फेफड़ों का कैंसर (non-small cell)
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
कहाँ जाना है
भारत के 13 hospital इस trial के लिए मरीज़ों को ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
स्पॉन्सर: Mirati Therapeutics Inc.
NCT04613596 on ClinicalTrials.gov
रजिस्ट्री पर आखिरी बार 13 Oct 2026 को अपडेट किया गया · हमने 20 Oct 2026 को देखा